Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

New treatments and novel diagnostic tests for neonatal seizures based on purinergic signaling.

Descrizione del progetto

Trovare bersagli per combattere le convulsioni neonatali

Il periodo neonatale, dalla nascita ai primi 28 giorni, è il momento più vulnerabile della vita per sviluppare convulsioni. Le crisi neonatali sono difficili da diagnosticare e trattare e la posta in gioco è alta. Le convulsioni possono portare a gravi danni allo sviluppo del cervello immaturo. Inoltre, numerosi elementi di prova suggeriscono che le convulsioni possono arrecare danni al cervello o esacerbare problemi esistenti a cui non siamo ancora preparati a rispondere. NeoPur ha identificato un recettore con proprietà anti-convulsive nei neonati. Chiarire il suo percorso di segnalazione dovrebbe aiutare a individuare i biomarcatori di convulsioni per diagnosi più accurate e risposte più rapide, nonché fornire potenziali bersagli terapeutici per un migliore controllo delle crisi.

Obiettivo

Newborns are predisposed to an increased risk of developing seizures following brain injury higher than in any other moment in a person’s life. Data from experimental models and patients suggest seizures in neonates may cause increased mortality and a higher risk of adverse neurological outcomes including cerebral palsy, developmental delay and intellectual disability. Consequently, the long-term health costs associated with seizures and neonatal brain damage are very high. To date, both diagnosis and treatment of neonatal seizures remain a clinical challenge with seizure misdiagnosis estimated to be as high as 50% and only every second patient responding to current therapies. The ATP-gated P2X7 receptor, a gatekeeper of inflammation, has recently emerged as a promising target for seizure control, showing anticonvulsant and disease-modifying properties in animals. New data produced by the supervisor now also suggest a role for P2X7 during seizures in neonates. However, to bring P2X7 further towards a clinical application, we need evidence of seizure-induced release of ATP in the brain, we must determine what are the clinical outcomes of a genetic and pharmacological targeting of P2X7 during neonatal seizures and we must identify biomarkers to better identify patients suffering from seizures. NeoPur brings together a team of experts in purinergic signalling, industrial partners developing novel P2X7 antagonists and diagnostic devices and clinicians specialised in neonates. This highly interdisciplinary and intersectoral approach will add a significant contribution to the understanding of purinergic signalling during neonatal seizures providing novel diagnostic and therapeutic approaches. The skills acquired during the research project, the excellent training record of the supervisor and host institution and the outstanding resources for learning and development available at RCSI will give me the tools necessary to become a highly employable neuroscientist.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

MSCA-IF-EF-ST - Standard EF

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) H2020-MSCA-IF-2018

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

ROYAL COLLEGE OF SURGEONS IN IRELAND
Contributo netto dell'UE
€ 184 590,72
Indirizzo
ST STEPHEN GREER 123
D02 YN77 DUBLIN 2
Irlanda
Regione
Ireland Eastern and Midland Dublin
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 184 590,72